Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO 20/20)

Toronto, Canada 28 March 2020 - 31 March 2020

Olaparib-bevacizumab PFS benefit in ovarian cancer greatest following upfront surgery

20 May 2020 by

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.

Olaparib-bevacizumab PFS benefit in ovarian cancer greatest following upfront surgery

20 May 2020

Subgroup findings boost benefit of niraparib in newly-diagnosed ovarian cancer

14 May 2020 by

The PARP* inhibitor niraparib improves progression-free survival (PFS) and is well-tolerated in women with newly diagnosed advanced ovarian cancer (OCa) after a response to first-line (1L) platinum-based chemotherapy (CT), subgroup results of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial have shown.

Subgroup findings boost benefit of niraparib in newly-diagnosed ovarian cancer

14 May 2020

Trametinib improves PFS in low-grade serous ovarian or peritoneal cancer

12 May 2020 by

Treatment with trametinib, an MEK inhibitor, significantly improves progression-free survival (PFS) in patients with recurrent low-grade serous ovarian or peritoneal carcinoma (LGSOC) compared with standard of care (SOC), according to a study presented at SGO 20/20.

Trametinib improves PFS in low-grade serous ovarian or peritoneal cancer

12 May 2020

Adding trastuzumab to chemo improves survival in HER2+ uterine serous carcinoma

11 May 2020 by

Adding trastuzumab to a chemotherapy backbone of carboplatin and paclitaxel led to sustained survival benefit in patients with recurrent/advanced, HER2-positive uterine serous carcinoma compared with chemotherapy alone, according to an updated survival analysis presented at SGO 2020 Meeting.

Adding trastuzumab to chemo improves survival in HER2+ uterine serous carcinoma

11 May 2020

Veliparib continues to show positive signals in ovarian cancer

08 May 2020 by

Subgroup analyses of the VELIA* trial showed that the concomitant administration of the poly(adenosine diphosphate-ribose) polymerase inhibitor veliparib with an induction chemotherapy (CT) regimen comprising carboplatin and paclitaxel (CP) generated antitumour activity and favourable safety in women with high-grade serous ovarian cancer.

Veliparib continues to show positive signals in ovarian cancer

08 May 2020

Frontline maintenance immunotherapy ups RFS in ovarian cancer

30 Apr 2020 by

Frontline maintenance treatment with a DNA engineered autologous tumour cell (EATC) immunotherapy yields relapse-free survival (RFS) benefit in patients with advanced epithelial ovarian cancer, particularly in those with wild-type BRCA1/2 status, according to the VITAL* study presented at the 2020 SGO Annual Meeting.

Frontline maintenance immunotherapy ups RFS in ovarian cancer

30 Apr 2020

Increased osteoporosis risk in young, gynae cancer survivors

30 Apr 2020 by

Young gynaecological cancer survivors have an increased risk of bone mineral density (BMD) reductions and osteoporosis, according to a study scheduled for presentation at SGO 20/20.

Increased osteoporosis risk in young, gynae cancer survivors

30 Apr 2020

Adjuvant HPV vaccine could reduce CIN2+ recurrence risk

27 Apr 2020 by

Receipt of an adjuvant human papillomavirus (HPV) vaccine following surgical excision could reduce the risk of cervical intraepithelial neoplasia (CIN2+) recurrence, according to a systematic review and meta-analysis submitted for presentation at SGO 20/20.

Adjuvant HPV vaccine could reduce CIN2+ recurrence risk

27 Apr 2020